Does seasonal level of serum 25-OH vitamin D correlate with the activity of crohn’s disease?

New Zealand Medical Journal

Volumn 127, Issue 1394, 2014, Pages 51-59

  Kini, Geogry Peter ^a   Young, Brian ^b   Herbison, Peter ^c   Schultz, Michael ^c  

^a DUNEDIN HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COLON RESECTION; CORRELATION ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX SCORE; DISEASE ACTIVITY; DISEASE ASSESSMENT; FEMALE; HEMATOCRIT; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; MASS SPECTROMETRY; OBSERVATIONAL STUDY; QUESTIONNAIRE; SEASONAL VARIATION; SUN EXPOSURE; SYMPTOM ASSESSMENT; VITAMIN BLOOD LEVEL; WINTER; ADOLESCENT; AGE; BLOOD; COHORT ANALYSIS; DIET SUPPLEMENTATION; FACTUAL DATABASE; MIDDLE AGED; NEW ZEALAND; PREDICTIVE VALUE; RISK ASSESSMENT; SEASON; SEX DIFFERENCE; SUNLIGHT; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COHORT STUDIES; CROHN DISEASE; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEASONS; SEX FACTORS; SUNLIGHT; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84905748542     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. van der Mei IA, Ponsonby AL, Blizzard L, et al. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology. 2001;20:168-174.
2. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17:2386-2392.
3. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr. 2007;85:1586-1591.
4. Holick MF. Vitamin D: importance in the prevention of cancers, type-1 diabetes, heart disease and osteoporosis. Am J Clin Nutr. 2004;79:362–371.
5. Gearry RB, Richardson AK, Framptom CM, et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25:325-33.
6. Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis. 2010;16:1550-6.
7. Molodeckey NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systemic review. Gastroenterology. 2012;142:46-54.
8. Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62(4):630-49.
9. Arnaud SB, Goldsmith RS, Lambert PW, Go VL. 25-Hydroxyvitamin D3: evidence of an enterohepatic circulation in man. Proc Soc Exp Biol Med. 1975;149:570–572.
10. Batchelor AJ, Watson G, Compston JE. Changes in plasma half-life and clearance of 3H-25- hydroxyvitamin D3 in patients with intestinal malabsorption. Gut 1982;23:1068-1071.
11. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol. 2004;39(6):527-33
12. Harries AD, Brown R, Heatley RV, Williams LA, et al. Vitamin D status in Crohn’s disease: association with nutrition and disease activity. Gut. 1985;26:1197-1203.
13. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25- dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285:2227–2231.
14. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122(4):867
15. Bentley RW, Keown D, Merriman TR, et al. Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Aliment Pharmacol Ther. 2011;33:855-856.
16. Noble CL, McCullough J, Ho W, et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:588-96
17. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 1995;61:638S–645S.
18. Zeng L, Anderson FH. Seasonal change in the exacerbations of Crohn’s disease. Scand J Gastroenterol. 1996;31:79-82.
19. Gilman J, Shanahan F, Cashman KD. Determinants of Vitamin D status in adult Crohn’s disease patients with particular emphasis on supplemental Vitamin D use. European Journal of Clinical Nutrition. 2006;60(7):889-896.
20. Joseph AJ, George B, Pulimood AB, et al. 25(OH) vitamin D level in Crohn’s disease: association with sun exposure and disease activity. Indian J Med Res. 2009 Aug; 130(2):133-7.
21. Statistics New Zealand: Subnational population estimates – at 30 June 2013. www.stats.govt.nz
22. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2008;624:55–71.
23. O’Neill R, Mahadevan U. Vitamin D status in inflammatory bowel disease: association with disease activity. Gastroenterology. 2011;140(Suppl 1):S-430.
24. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. J Parenter Enteral Nutr. 2011;35(3):308-16.